A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy

Qingfeng Pharmaceutical

Status

Unknown

Conditions

Focal-Onset Seizure

Epilepsy

Treatments

Drug: lacosamide

Study type

Observational

Funder types

Industry

Identifiers

NCT04737837

QF-LCM2020-1

Details and patient eligibility

About

The purpose of this trial is to evaluate the efficacy, safety, and pharmaco-economics of Lacosamide Tablet as first add-on therapy for uncontrolled focal onset epilepsy ,invetigating effects of lacosamide Tablet on cognitive function of children and anxiety and depression of adults with focal onset seizures In real-world clinical setting

Full description

In many real world, lacosamide as the first add-on therapy can significantly improve the seizure freedom rate. Moreover, many pharmacoeconomic studies in Sweden and the United States have confirmed that lacosamide is a more cost-effective option.This is a real-world study to evaluate the efficacy, safety and cost-effectiveness of Generic lacoxamide tablets in the treatment of patients with focal epilepsy. During the trial, patients with focal epilepsy were treated with lacosamide for the first time after the failure of the original antiepileptic drug. At the same time, the cost-effectiveness of Generic lacosamide was evaluated from the perspective of economics, in order to provide the basis for the clinical choice for Chinese epilepsy patients.

Enrollment

200 estimated patients

Sex

All

Ages

4 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Before the start of the trial, to obtain the informed consent approved by the ethics committee voluntarily signed by each subject. For underage subjects, the informed consent jointly signed by the subjects themselves (≥10 years ) and their parents or legal guardian (in which the underage needs the signature with their parents or legal guardian, and the underage is defined as the subject under 18 years of age) ;
Male and female, between the ages of 4 and 75 years;
Diagnostic criteria of focal onset seizures (with or without focal to bilateral tonic clonic seizures) was based on the 2017 Classification of Epileptic Seizures from the International League Against Epilepsy (ILAE);
In the 4 weeks before enrollment and during the baseline period, patients have been on only one stable dosage of antiepileptic drug and suitable for lacosamide add-on therapy according to their investigators criteria;
During the 8-week retrospective baseline period, patients must have had at least 4 focal onset seizures per 28 days on average.

Exclusion criteria

Patients had received previous lacosamide treatment;
Female patients are pregnant, breast-feeding, and will not use contraception during the trial;
Patients had known allergies to lacosamide or any ingredients of the drug, or with allergic constitution;
Patients have a history of status epilepticus in the last 12 months;
History of chronic alcohol or drug abuse; 6.history of suicide attempt or suicidal ideation in the past 6 months;
Current use of Antidepressants, anxiolytics or antipsychotics;
Patients suffer from progressive diseases that affect the patient's brain and its function;
Sychogenic nonepileptic seizures;
Patients suffer from serious lung and blood system diseases, malignant tumor, lower immune function and psychosis;
Patients wil receive ketogenic diet therapy, or Four weeks before entering the screening period, patients used other drugs that may affect the absorption, distribution, metabolism and excretion of lacosamide, such as antipsychotics, monoamine oxidase inhibitors, barbiturates (except for combined use as anticonvulsant therapy), narcotic analgesics.
Patients Had epilepsy brain surgery, or will undergo epilepsy surgery in the next four months.
Investigators considered Patients as unsuitable for this trial.